1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Natera, Inc.
  6. News
  7. Summary
    NTRA   US6323071042

NATERA, INC.

(NTRA)
  Report
Delayed Nasdaq  -  04:00 2022-08-09 pm EDT
50.82 USD   -2.57%
08/05JPMorgan Adjusts Natera's Price Target to $100 from $80, Keeps Overweight Rating
MT
08/05NATERA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/04NATERA : Q2 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Natera : Q2 2022 Earnings Presentation

08/04/2022 | 05:43pm EDT

Natera, Inc.

Investor presentation

Second Quarter 2022 Earnings Call

August 4, 2022

Safe harbor statement

This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our proposed products and launch schedules, our reimbursement coverage and our product costs, our commercial partners and potential acquisitions, our user experience, our clinical trials and studies, our financial performance, our strategies, our anticipated revenue and financial outlook, our goals and general business and market conditions, are forward-looking statements.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to maintain our business and operations as planned due to disruptions and economic uncertainty caused by the COVID-19 pandemic; we may be unable to further increase the use and adoption of Panorama and Horizon through our direct sales efforts or through our laboratory partners; we may be unable to develop and successfully commercialize new products, including Signatera and Prospera; we have incurred losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; we may need to raise additional capital to support our business plans, which may not be available when necessary or on favorable terms; we may not be successful in commercializing our cloud-based distribution model; our products may not perform as expected; the results of our clinical studies, including our SNP-based Microdeletion and Aneuploidy RegisTry, or SMART, Study, may not be compelling to professional societies or payors as supporting the use of our tests, particularly in the average-risk pregnancy population or for microdeletions screening, or may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratory facilities becomes inoperable, we will be unable to perform our tests and our business will be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for Panorama, Horizon and our other tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors, such as the increased focus by third-party payers on requiring that prior authorization be obtained prior to conducting a test; if the FDA were to begin actively regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval and incur costs associated with complying with post-market controls; litigation or other proceedings, resulting from either third party claims of intellectual property infringement or third party infringement of our technology, is costly, time-consuming and could limit our ability to commercialize our products or services; any inability to effectively protect our proprietary technology could harm our competitive position or our brand; and we cannot guarantee that we will be able to service and comply with our outstanding debt obligations or achieve our expectations regarding the conversion of our outstanding convertible notes. We discuss these and other risks and uncertainties in greater detail in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports on Forms 10-K and 10-Q and in other filings we make with the SEC from time to time. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and our actual results could differ materially and adversely from those anticipated or implied. As a result, you should not place undue reliance on our forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. We file reports, proxy statements, and other information with the SEC. Such reports, proxy statements, and other information concerning us is available at http://www.sec.gov. Requests for copies of such documents should be directed to our Investor Relations department at Natera, Inc., 13011 McCallen Pass, Building A Suite 100, Austin, TX 78753. Our telephone number is (650) 249-9090.

Not for reproduction or further distribution.

2

Recent highlights

  • Total revenues of $198.2M; ~40% growth over Q2 21
  • ~500K total tests processed in Q2 22; ~33% growth vs. Q2 21
  • 2022 revenue guidance raised to $805 million - $825 million
  • Selected to participate in UHC's Preferred Laboratory Network after a rigorous review process
  • Publication of the Trifecta study for Prospera Kidney in Transplantation; largest prospective, multisite, fully biopsy matched study to date
  • Completed enrollment in RenaCARE study for Renasight, with more than 1,700 patients at 30+ sites
  • Secured Medicare coverage for muscle invasive bladder cancer; fourth coverage decision for Signatera
  • Presented substantial new Signatera data sets at the 2022 ASCO Annual Meeting
  • Appointed Dr. Minetta Liu as CMO for Oncology
  • Additional equity investment in Natera by Executive Chairman Matt Rabinowitz

Not for reproduction or further distribution.

3

Record Q2 22 volume of 500,000 units

~33% volume growth

Total processed units

over Q2 21

(in thousands)

  • Strong market share gains in Women's Health
  • Continued momentum in Organ Health and Oncology
  • Overcame normal Q1 to Q2 sequential seasonality

489K

500K

407K

439K

376K

348K

262K

295K

235K

234K

200K

200K

209K

195K

Q1 19

Q2 19

Q3 19

Q4 19

Q1 20

Q2 20

Q3 20

Q4 20

Q1 21

Q2 21

Q3 21

Q4 21

Q1 22

Q2 22

Not for reproduction or further distribution.

4

Revenues accelerating with volume growth

~40% revenue

Total revenues: year on year trend

growth over Q2 21

($ in millions)

$198

Steady NIPT ASP growth

40%

Strong sequential ASP

$142

growth in Oncology:

64%

Medicare mix

18%

16%

$86

improving

$63

$74

Volume shift

to recurrence

monitoring

Q2 18

Q2 19

Q2 20

Q2 21

Q2 22

Not for reproduction or further distribution.

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Natera Inc. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 21:36:04 UTC.


© Publicnow 2022
All news about NATERA, INC.
08/05JPMorgan Adjusts Natera's Price Target to $100 from $80, Keeps Overweight Rating
MT
08/05NATERA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
08/04NATERA : Q2 Earnings Snapshot
AQ
08/04NATERA : Q2 2022 Earnings Presentation
PU
08/04Natera Q2 Net Loss Widens but Matches Street View; Revenue Rises Almost 40%, Topping An..
MT
08/04NATERA : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/04TRANSCRIPT : Natera, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04Earnings Flash (NTRA) NATERA Posts Q2 Revenue $198.2M
MT
08/04Natera Revised Revenue Guidance for the Full Year of 2022
CI
08/04Natera Reports Second Quarter 2022 Financial Results
PR
More news
Analyst Recommendations on NATERA, INC.
More recommendations
Financials (USD)
Sales 2022 819 M - -
Net income 2022 -565 M - -
Net cash 2022 84,3 M - -
P/E ratio 2022 -8,74x
Yield 2022 -
Capitalization 4 927 M 4 927 M -
EV / Sales 2022 5,91x
EV / Sales 2023 4,88x
Nbr of Employees 2 670
Free-Float 96,1%
Chart NATERA, INC.
Duration : Period :
Natera, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NATERA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 50,82 $
Average target price 84,91 $
Spread / Average Target 67,1%
EPS Revisions
Managers and Directors
Stephen Chapman Chief Commercial Officer
Michael Burkes Brophy VP-Corporate Development & Investor Relations
Matthew Rabinowitz President, Chief Executive Officer & Director
Eric A. Evans Chief Scientific Officer
Rishi Kacker Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
NATERA, INC.-45.58%5 057
BIOMÉRIEUX-14.29%12 937
DIASORIN S.P.A.-18.24%7 573
LANTHEUS HOLDINGS, INC.174.11%5 435
10X GENOMICS, INC.-70.80%4 931
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.-8.47%4 751